,
Pollock, Richard F. http://orcid.org/0000-0002-9873-7507
Valentine, William J.
Marso, Steven P.
Andersen, Andreas
Gundgaard, Jens
Hallén, Nino
Tutkunkardas, Deniz
Magnuson, Elizabeth A.
Buse, John B.
Article History
First Online: 2 July 2019
Compliance with Ethical Standards
: This article does not contain any new studies with human participants performed by any of the authors.
: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
: Sponsorship for the DEVOTE clinical trial, this study and article processing charges were funded by Novo Nordisk A/S.
: RFP and WV contributed to the model design. RFP programmed the model, identified appropriate model parameters from the literature, and ran the analyses. WV reviewed the final model and analyses. All authors reviewed the manuscript, contributed to the interpretation of results, revised the manuscript critically for intellectual content and approved the final version to be published. All authors agree to be accountable for the parts of the work he or she has done and confirm they fulfil the ICMJE authorship criteria.
: RFP was at the time of the study and WV is a full-time employee of Ossian Health Economics and Communications GmbH, which received consultancy fees from Novo Nordisk to construct the model and conduct the analyses. EAM reports research support from Abbott Vascular, Boston Scientific, Cardiovascular Systems, Inc., Daiichi Sankyo and Medtronic. JB reports grant and consultation fees to the University of North Carolina (UNC) under contract and travel/meals/lodging for contracted activities from Novo Nordisk during the conduct of the study and salary support from the National Institutes of Health (UL1TR002489); fees for consultation to UNC under contract and travel/meals/lodging for contracted activities from Adocia, AstraZeneca, Dexcom, Elcelyx Therapeutics, Eli Lilly, Intarcia Therapeutics, Lexicon, MannKind, Metavention, NovaTarg, Novo Nordisk, Sanofi, Senseonics, and vTv Therapeutics; grants from AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Lexicon, Novo Nordisk, Sanofi, Theracos, and vTv Therapeutics; stock options in Mellitus Health, PhaseBio and Stability Health outside the submitted work. He is a consultant to Neurimmune AG. AA, DT, JG and NH are all employees of Novo Nordisk, and AA, DT and JG also hold shares/stocks in Novo Nordisk. SM has received personal fees from Abbott Vascular, Novo Nordisk, Boston Scientific Asahi, Boehringer-Ingelheim and Bristol-Myers Squibb; and research support from Novo Nordisk.